- Molecular Partners puts IPO on hold
October 21, 2014
- Molecular Partners launches IPO on SIX Swiss Exchange
September 23, 2014
Molecular Partners is advancing a growing pipeline of DARPin therapies for the treatment of severe or life-threatening diseases, with an initial focus on ophthalmology and oncology. The company is developing its most advanced product candidate, abicipar, in partnership with Allergan for the treatment of wet age-related macular degeneration (wet AMD), a leading cause of blindness.
We collaborate with leading pharmaceutical companies, including Allergan, Janssen and Roche, to discover and develop DARPin therapies.
Working together, we aim to speed the delivery of breakthrough therapies for serious diseases while creating value for both sides of the partnership.